Fong K M, Zimmerman P V, Smith P J
Queensland Cancer Fund Research Unit, Department of Pathology, University of Queensland Medical School, Herston.
Pathology. 1995 Oct;27(4):295-301. doi: 10.1080/00313029500169173.
In Australia, lung cancer is the most common malignancy in males and the largest cause of cancer deaths. Conventional management has not had a dramatic impact on the mortality rates from lung cancer, which has a case-fatality rate of over 90%. Recent developments in molecular and cellular biology have however, contributed to our knowledge of lung tumorigenesis, which will hopefully translate into clinical benefit for our patients. Many molecular abnormalities are common to both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) but there are differences between these histological types and even within the NSCLC subtypes. This review concentrates on NSCLC, which accounts for up to 85% of Australian lung cancers.
在澳大利亚，肺癌是男性中最常见的恶性肿瘤，也是癌症死亡的主要原因。传统治疗方法对肺癌死亡率并未产生显著影响，肺癌的病死率超过90%。然而，分子和细胞生物学的最新进展有助于我们了解肺肿瘤的发生机制，有望为患者带来临床益处。非小细胞肺癌（NSCLC）和小细胞肺癌（SCLC）存在许多共同的分子异常，但这些组织学类型之间甚至NSCLC亚型内部都存在差异。本综述主要关注NSCLC，它占澳大利亚肺癌病例的85%。
